![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
December 23, 2024
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
December 23, 2024
Summaries of presentations at the 2024 San Antonio Breast Cancer Symposium as well as the 66th American Society of Hematology Annual Meeting and Exposition in San Diego
December 23, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
November 25, 2024
Several themes emerged as key areas of focus for ECOG-ACRIN during the Fall 2024 Group Meeting
November 25, 2024
EA5162 is testing a new therapy for certain patients with advanced NSCLC who have developed resistance to other treatments
November 25, 2024
October 17, 2024
The co-chairs reflect on how the cancer research landscape has evolved over the last five years
October 17, 2024
In August, the cancer research community lost a leader in the fields of breast cancer and surgical oncology
October 17, 2024
The Patient-Reported Outcomes (PRO) Advisory Group guides study investigators on how best to include PRO measures and endpoints in clinical trials
October 17, 2024
The Journal of Clinical Oncology has published a proposal to jump-start correlative research, which is almost at a standstill
October 17, 2024
The changes aim to alleviate scheduling difficulties during the randomization step, and they introduce the new tumor test for this phase 2 trial testing radiotherapy with or without chemotherapy
October 17, 2024
Summaries of recently published ECOG-ACRIN research results